LAUSR

The natural history of cerebral amyloid angiopathy–related inflammation (CAA-ri) was carefully explored in the recent longitudinal, clinical, and radiographic study led by Dr. Antolini and colleagues. In their analysis of 113 patients with CAA-ri (11% definite CAA-ri, 72% probable, 18% possible), approximately 80 percent of patients recovered clinically and radiographically by 12 months. The rate of recurrent CAA-ri after resolution of the index event was 38% within the subsequent 24 months and was significantly more common when intravenous corticosteroids were suddenly discontinued without a slow oral steroid taper. Dr. Filippi et al. noted that β-amyloid–targeting autoantibodies in the CSF may be useful prognostic biomarkers and can be leveraged to trend responsiveness to treatments such as corticosteroids. The investigators agree that the screening and monitoring of these biomarkers may be used in future clinical trials for patient selection and in the biological assessment of treatment response.